ArticleVaccines2023
Measles Immunity Status of Greek Population after the Outbreak in 2017-2018: Results from a Seroprevalence National Survey.
Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 4 citations in OpenAlex.
- Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.Open forum infectious diseases · 2026Article
- Assessment of Measles Immunity in the Croatian Population: A Retrospective Seroprevalence Study, 2015-2025.Vaccines · 2026Article
- Measles Seroprevalence Among Healthcare Workers in a Tertiary Hospital in Central Greece, 2017.Vaccines · 2026Article
- Evaluation of measles immunity in the central black sea region of Türkiye.BMC infectious diseases · 2026Article
- A cross-sectional study of seroprevalence in Armenia, 2025: measles, mumps, rubella, and diphtheria.Frontiers in public health · 2026Article
- A Nationwide Seroprevalence Study for Measles in Individuals of Fertile Age in Romania.Antibodies (Basel, Switzerland) · 2025Article
- A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China.Vaccines · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate data on susceptibility rates against measles in the general population of Greece are scarce. Many studies have estimated the vaccination coverage, but none have calculated the nationwide immunity rate, including all age groups, against the measles virus. The purpose of our study was to determine the measles immunity status, especially after the latest outbreak in 2017-2018. In total, 3972 leftover blood samples were obtained during 2020-2021. They were collected from a nationwide laboratory network using a geographically stratified sampling strategy and were tested for the presence of measles-specific IgG antibodies. The overall crude seroprevalence was calculated to be 89.6% and the adjusted was 89.8% (95% CI: 88.8-90.8%). There was no statistically significant difference in seropositivity between sexes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.